The ROE as of November 2024 (TTM) for Werewolf Therapeutics, Inc. (HOWL) is -58.83%

According to Werewolf Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is -58.83%. This represents a change of 293.61% compared to the average of -14.95% of the last 4 quarters.

Werewolf Therapeutics, Inc. (HOWL) Historical ROE (quarterly & annually)

How has HOWL ROE performed in the past?

The mean historical ROE of Werewolf Therapeutics, Inc. over the last ten years is -6.85%. The current -58.83% ROE has changed 758.82% with respect to the historical average. Over the past ten years (40 quarters), HOWL's ROE was at its highest in in the December 2020 quarter at 14.27%. The ROE was at its lowest in in the March 2020 quarter at -39.17%.

Werewolf Therapeutics, Inc. (HOWL) ROE by Quarter and Year

Discovering the peaks and valleys of Werewolf Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Werewolf Therapeutics, Inc. (HOWL) Average ROE

How has HOWL ROE performed in the past?

The current ROE of Werewolf Therapeutics, Inc. (HOWL) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Werewolf Therapeutics, Inc. (HOWL) ROE vs. Peers

How is HOWL’s ROE compared to its peers?

Werewolf Therapeutics, Inc.’s ROE is greater than Monte Rosa Therapeutics, Inc. (-62.68%), greater than Design Therapeutics, Inc. (-18.01%), greater than Ikena Oncology, Inc. (-39.59%), greater than Stoke Therapeutics, Inc. (-54.45%), greater than Edgewise Therapeutics, Inc. (-26.83%), greater than Decibel Therapeutics, Inc. (-56.38%), greater than Celcuity Inc. (-62.66%), greater than C4 Therapeutics, Inc. (-42.45%), greater than Talaris Therapeutics, Inc. (-14.93%), greater than Adicet Bio, Inc. (-53.85%), greater than Cullinan Oncology, Inc. (-26.54%), greater than Vor Biopharma Inc. (-101.14%), greater than Third Harmonic Bio, Inc. (-4.28%), greater than Passage Bio, Inc. (-72.53%), greater than Acrivon Therapeutics, Inc. Common Stock (-47.95%), greater than Eliem Therapeutics, Inc. (-47.03%), greater than Molecular Partners AG (-39.16%), greater than MediciNova, Inc. (-20.70%), greater than Anebulo Pharmaceuticals, Inc. (-184.40%), less than Champions Oncology, Inc. (323.52%), greater than Cyteir Therapeutics, Inc. (-9.44%),

Build a custom stock screener for Werewolf Therapeutics, Inc. (HOWL) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Werewolf Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Werewolf Therapeutics, Inc. (HOWL) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Werewolf Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.